Second Quarter and First Half 2011 Conference Call. 29 July, SORIN GROUP Presentation 1

Transcription

1 Second Quarter and First Half 2011 Conference Call 29 July, 2011 SORIN GROUP Presentation 1

2 DISCLAIMER This presentation contains management preliminary estimates and forward-looking statements, including information related to Sorin projected financial performance and the expected development of the med-tech industry, in particular in the cardiovascular segment. These statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, as of this date, though by their nature future estimates are uncertain and difficult to predict. Actual results or experience could differ materially from the information contained herein. This communication does not constitute an offer or solicitation for the sale, purchase or acquisition of securities of any of the companies mentioned in any jurisdiction. SORIN GROUP Presentation 2

3 KEY ACHIEVEMENTS Q H 2011 Top line growth +0.6%* Revenue growth vs Q Strong increase in profitability Gross Margin of 59.6% vs 59.4% in Q EBITDA Margin of 18.3% vs 16.2% in Q Net Profit up 54.4% to 17.1m R&D expenses increased from 8.7% to 9.4% of Revenues Top line growth +2.6%* Revenue growth vs H Strong increase in profitability Gross Margin of 59.5% vs 58.8% in H EBITDA Margin of 16.7% vs 15.4% in H Net Profit up 66.8% to 29.9m R&D expenses increased from 8.8% to 9.4% of Revenues Further reduction in Net Debt to 101.7m as of June 30, 2011 vs 115.8m as of March 31, 2011 and 171.2m as of June 30, 2010 * At comparable FX rates and perimeter SORIN GROUP Presentation 3

4 Q RESULTS TOP-LINE GROWTH: 191.9m (+0.6%)* Data in m and % Cardiopulmonary Q Revenues 86.8 Underlying growth* +5.9% Cardiac Rhythm Management % Heart Valves % Cardiopulmonary: Strong performance from all three businesses Cardiac Rhythm Management: Global market slowdown Heart Valves: Strong growth of mechanical valves * At comparable FX rates and perimeter SORIN GROUP Presentation 4

5 Q RESULTS CARDIOPULMONARY: 86.8 m (+5.9%)* Data in m and % Heart-lung machines Q Revenues 17.5 Underlying growth* +17.8% Oxygenators % Autotransfusion devices % Heart-lung machines Strong performance in Emerging markets and in the US Oxygenators Solid performance in Emerging markets and in the US, helped by the Gish integration Continuous focus on LinoX: CE mark in Q Autotransfusion devices Strong growth mainly from European countries Successful launch of Xtra * At comparable FX rates and perimeter SORIN GROUP Presentation 5

6 CARDIOPULMONARY ACQUISITION OF ESTECH CANNULAE PRODUCT LINE Femoral Venous cannulae Vascular access kits EasyFlow Arterial cannulae FlexFlow Venous cannulae product overview Femoral venous cannulation Femoral cannulation Dispersion flow tip for direct and femoral arterial cannulation Vacuum assisted venous drainage via direct right atrial cannulation Transaction details Deal closed on July 1 st, 2011 Annual sales of around US$3m Quick and effective execution Enter into highly profitable and fast growing Cannulae for Minimally Invasive Cardiac Surgery* Asset purchase agreement (no headcount) Sales transition and product integration starting Q Leverage on Sorin Cardiopulmonary distribution channel Follows the exclusive distribution agreement for Calmed s products in the US and Europe (April 2011) This deal strengthens Sorin market positioning in the cannulae business and further consolidates the Group s relationship with cardiac surgeons worldwide * Heart valve repair and replacement procedures performed with minimally invasive access and cardiopulmonary bypass SORIN GROUP Presentation 6

7 Q RESULTS CARDIAC RHYTHM MANAGEMENT: 72.8m (-6.1%*) Data in m and % High Voltage Q Revenues 23.0 Underlying growth* -11.7% Low Voltage % Global market slowdown No contribution from new product launches Continuous focus on Remote Monitoring and SonR technology: CE mark expected in Q * At comparable FX rates and perimeter SORIN GROUP Presentation 7

8 CARDIAC RHYTHM MANAGEMENT REMOTE MONITORING AND SONR TECHNOLOGY Remote Monitoring Innovative algorithms with intelligent diagnostic features A user interface built on user center design principles Cutting-edge technology for safe and effective data transmission At Europace (June 2011) Sorin presented SMARTVIEW Remote Monitoring Solution (with live demo and user interface on the Sorin booth) CE mark expected for Q SonR: Redefining what s possible SonR is the only weekly, self-adjusting CRT optimization system providing optimized timing at rest and exercise for improved CRT response 100 patients enrolled in Clinical Trial with 1 and 3 months follow-up CE mark and Validation Review expected in 4Q 2011, followed by European commercial launch First implant of new RESPOND CRT trial planned for Q SORIN GROUP Presentation 8

9 Q RESULTS HEART VALVES: 31.7m (+3.7%*) Data in m and % Mechanical Valves Q Revenues 15.5 Underlying growth* +4.3% Tissue Valves % Mechanical Valves Strong growth, primarily in Emerging markets, more than offset the continued shift of the market to tissue valves Tissue Valves Growth driven by Mitroflow in the US and Perceval in Europe Continuous focus on sales execution and new products New Mitroflow valve with Phospholipid Reduction Treatment (CE mark obtained in July 2011) New size valve of 25mm for Perceval (CE mark expected by end of 2011) * At comparable FX rates and perimeter SORIN GROUP Presentation 9

10 HEART VALVES PERCEVAL S: A REVOLUTION IN CARDIAC SURGERY Key features and clinical benefits Built on a proven Sorin Biological Valve Freedom SOLO heart valve prothesis Self-expanding, super-elastic alloy frame Self-anchoring device and truly sutureless Ideal for Minimally Invasive Surgical approach Significant procedure time reduction Up to 50% cross-clamp time reduction Excellent hemodynamic results and durability Potentially less pain and risk of infection, less mechanical ventilation and reduction of patient ICU and hospital length of stay and relative costs Update Over 700 patients implanted worldwide Procedures performed in 13 countries Including Canada in special access scheme Highly positive response from cardiac surgeons Strong market interest on sutureless/ fast deployment valves Acceptance of the pricing strategy Tactical commercial launch: focused customer segmentation Regulatory process for FDA on track (finalized FDA clinical strategy; approval expected in 2014) Market access / reimbursement procedures ongoing Next steps Size range extension Extended indications (>65YOA) MIS introducers Further development programs associated to new potential markets (e.g., robotics) SORIN GROUP Presentation 10

11 Q RESULTS COST CONTAINMENT & INNOVATION Gross Profit SG&A R&D Data in m Data in m Data in m % % 59.4% 59.6% 39.9% 36.9% % 8.7% 9.4% Q Q Q Q Q Q Negative impact of FX translation for approx. 4m Gross Margin expansion driven by manufacturing efficiencies partially offset by a less favorable product mix and a negative FX impact Favorable impact of FX translation for approx. 2.5m and of hedging for 3.5m SG&A sharp reduction due to financial discipline and the above-mentioned FX and hedging results Increase of R&D spending Remote Monitoring & SonR Clinical trials for Perceval and SOLO LinOx industrialization SORIN GROUP Presentation 11

12 Q RESULTS PROFITABILITY EBITDA EBIT Net profit Data in m Data in m Data in m % 16.2% 18.3% Q Q % 13.0% 11.0% Q Q % % 5.6% Q Q th quarter in a row of year over year EBITDA growth Excluding special items EBIT amounted to 25.6m ( 21.3m in Q2 2010) Improved operating profit Lower interest expenses Decrease of average net debt Lower spread applied to M/L term debt One-time FX gains SORIN GROUP Presentation 12

13 H FINANCIAL RESULTS Data in m, unless specified H H Growth Revenues %* Gross Profit Gross Margin % % +2.3% EBITDA EBITDA Margin % % +10.2% EBIT EBIT Margin % % +24.9% Net Profit % % +66.8% * At comparable FX rates and perimeter SORIN GROUP Presentation 13

14 Q RESULTS NET DEBT Net Debt Evolution Data in m /06/ /12/ /03/ /06/2011 Significant decrease in Net Debt of 69.5m in the last 12 months, despite a deterioration in the collection cycle particularly in Spain Positive contribution of special items for 24.4m ( 7m in Q2 2011) Net debt/ebitda as of June 30, 2011 at 0.8x On 29 July 2011 Sorin executed voluntary full prepayment of the syndicated loan ( 12.4m) SORIN GROUP Presentation 14

15 GUIDANCE Q Guidance Revenue growth* flat* Net Profit 10-12m For full year 2011, Sorin expects to exceed the high-end of its net profit guidance, while 2011 revenues are expected to be at the low-end of the guidance range *At comparable FX rates and perimeter Ref. press release dated February 10, 2011 SORIN GROUP Presentation 15